These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33439367)

  • 1. Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review.
    Hammeken LH; Baunwall SMD; Hvas CL; Ehlers LH
    Health Econ Rev; 2021 Jan; 11(1):3. PubMed ID: 33439367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent
    Abdali ZI; Roberts TE; Barton P; Hawkey PM
    EClinicalMedicine; 2020 Jul; 24():100420. PubMed ID: 32637898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of economic evaluation in fecal microbiota transplantation.
    Stalder T; Kapel N; Diaz S; Grenouillet F; Koch S; Limat S; Daval F; Vuitton L; Nerich V
    Infect Control Hosp Epidemiol; 2020 Apr; 41(4):458-466. PubMed ID: 31973773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.
    Varier RU; Biltaji E; Smith KJ; Roberts MS; Kyle Jensen M; LaFleur J; Nelson RE
    Infect Control Hosp Epidemiol; 2015 Apr; 36(4):438-44. PubMed ID: 25782899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
    Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
    BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
    Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
    Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
    Luo Y; Lucas AL; Grinspan AM
    Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review with meta-analysis: encapsulated faecal microbiota transplantation - evidence for clinical efficacy.
    Cold F; Baunwall SMD; Dahlerup JF; Petersen AM; Hvas CL; Hansen LH
    Therap Adv Gastroenterol; 2021; 14():17562848211041004. PubMed ID: 34484424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
    Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
    PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
    Merlo G; Graves N; Brain D; Connelly LB
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection.
    Shaffer SR; Witt J; Targownik LE; Kao D; Lee C; Smieliauskas F; Rubin DT; Singh H; Bernstein CN
    J Infect; 2020 Nov; 81(5):758-765. PubMed ID: 32980389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal microbiota transplantation for recurrent
    Baunwall SMD; Lee MM; Eriksen MK; Mullish BH; Marchesi JR; Dahlerup JF; Hvas CL
    EClinicalMedicine; 2020 Dec; 29-30():100642. PubMed ID: 33437951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal microbiota transplantation for recurrent
    Sandhu A; Chopra T
    Therap Adv Gastroenterol; 2021; 14():17562848211053105. PubMed ID: 34992678
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
    Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Recurrent
    Azimirad M; Yadegar A; Gholami F; Shahrokh S; Asadzadeh Aghdaei H; Ianiro G; Suzuki H; Cammarota G; Zali MR
    J Inflamm Res; 2020; 13():563-570. PubMed ID: 32982371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in patients with recurrent
    Hammeken LH; Baunwall SMD; Dahlerup JF; Hvas CL; Ehlers LH
    Therap Adv Gastroenterol; 2022; 15():17562848221078441. PubMed ID: 35463939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.